Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.0452 | 0.2543 | 0.2543 |
Brugia malayi | endoprotease bli-4 precursor | 0.0699 | 0.4952 | 1 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0699 | 0.4952 | 1 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.0438 | 0.2409 | 0.2409 |
Echinococcus granulosus | furin | 0.0699 | 0.4952 | 0.4952 |
Schistosoma mansoni | furin-1 (S08 family) | 0.0296 | 0.1025 | 0.207 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.0699 | 0.4952 | 1 |
Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.1218 | 1 | 1 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0438 | 0.2409 | 1 |
Schistosoma mansoni | memapsin-2 (A01 family) | 0.0492 | 0.2932 | 0.592 |
Loa Loa (eye worm) | hypothetical protein | 0.0261 | 0.0689 | 0.1392 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.0452 | 0.2543 | 0.2543 |
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0248 | 0.0556 | 0.5 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.0438 | 0.2409 | 0.2409 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0438 | 0.2409 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0699 | 0.4952 | 1 |
Brugia malayi | celfurPC protein | 0.0543 | 0.3434 | 0.3699 |
Echinococcus multilocularis | 0.0543 | 0.3434 | 0.3434 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Survival (ADMET) | = 56.4 % | Intrinsic cytotoxicity against human K562 cells assessed as cell survival at 10 uM after 24 hrs by MTT assay | ChEMBL. | 25634041 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.